[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337001-105":59,"doc-detail-337001-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","murine-colon-cancer-derived-cells-exhibit-heterogeneous-resistance-profiles-against-an-oncolytic-virus","Murine colon cancer derived cells exhibit heterogeneous resistance profiles against an oncolytic virus","","Murine colon cancer derived cells show heterogeneous resistance to oncolytic virotherapy, limiting the effectiveness of viral cancer treatments. The study investigates additional resistance mechanisms beyond chronic innate immune activation by isolating two resistant CT26-derived clones against VSV-D51. One clone displays a strong resistance profile linked to increased cytokine-mediated antiviral responses, while the other shows partial resistance involving cytoskeletal reorganization, small GTPase signaling, and structural cell changes. Results highlight tumor cell capability to deploy diverse defenses against oncolytic viruses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/murine-colon-cancer-derived-cells-exhibit-heterogeneous-resistance-profiles-against-an-oncolytic-virus/337001/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/murine-colon-cancer-derived-cells-exhibit-heterogeneous-resistance-profiles-against-an-oncolytic-virus/337001.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What virus and cell model are used to study resistance mechanisms?","Question",{"text":112,"@type":113},"The study focuses on VSV-D51 and murine colon carcinoma CT26 cells. Two CT26-derived resistant clones (C1 and C4) are isolated to compare distinct resistance behaviors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the resistance profile differ between the two clones?",{"text":117,"@type":113},"One clone shows strong resistance associated with elevated cytokine-mediated antiviral responses. The other clone shows lower-level resistance involving cytoskeletal reorganization, small GTPase signaling, and cell structural changes.",{"name":119,"@type":110,"acceptedAnswer":120},"What do the findings suggest about oncolytic virotherapy resistance?",{"text":121,"@type":113},"Tumor cells can deploy heterogeneous resistance mechanisms against oncolytic viruses, which can act as a barrier and influence therapeutic efficacy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337001,1790025264,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMurine colon cancer derived cells exhibit heterogeneous resistance profiles against an oncolytic virus  \nAlejandra Larrieux & Rafael Sanjuán􀀍  \nOncolytic virotherapy has shown efficacy in various animal models and a few human cancers. However, there are still significant limitations for the implementation of these therapies. One such limitation is the emergence of cellular resistances, which may appear rapidly considering the high genetic heterogeneity of most tumors. We previously showed that cellular resistance to an oncolytic virus can be mediated by the chronic activation of innate immunity. Here, we explored the existence of additional resistance mechanisms in murine colon cancer-derived cells. For this purpose, we isolated two cellular clones that were resistant to the oncolytic virus VSV-D51. While one of the clones showed a strong resistance profile associated with increased cytokine-mediated antiviral responses, the other clone showed a lower level of resistance that involves cytoskeletal reorganization, signaling by small GTPases, and cell structural changes. These results demonstrate the capacity of tumor cells to deploy heterogeneous mechanisms of resistance to oncolytic viruses.  \nKeywords Oncolytic virus, Vesicular stomatitis virus, Cellular resistance, Antiviral response, Innate immunity  \nOncolytic viruses are promising biotherapies that exploit cellular vulnerabilities to selectively infect and replicate within tumor cells, while exempting healthy cells from the infectious process1–3. An extensive body of experimental evidence, conducted using both natural and engineered oncolytic viruses, such as vesicularstomatitis virus (VSV), adenovirus, herpes simplex virus, and Newcastle disease virus, among others, supports the efficacy of this therapeutic approach4. However, as other cancer therapies, oncolytic virotherapies encounter resistance challenges, including antibody and cellular responses5, interferon (IFN)-mediated resistance6,7, epigenetic modifications8,9, inactivation of cell death mechanisms, insensitivity to growth suppressor signals, and spatial barriers10, 11, among many others12. For instance, many oncolytic viruses are particularly sensitive to interferon (IFN)-mediated cellular antiviral responses, and their efficacy is thus dependent on the degree of disruption of IFN signaling shown by target cells13. Unfortunately, a significant percentage of tumor cells retain intact IFN signaling, as well as constitutive expression ofIFN-stimulated genes (ISGs) and resistance gene signatures14–17. Therefore, the emergence of immune-based cellular resistance in populations initially susceptible to infection represents a barrier to the development of oncolytic viruses and determines their efficacy10, 16–18.  \nVSV, a member ofthe Rhabdoviridae family, is a single-stranded negative-sense RNA virus with a relatively small genome size (11.2 kb), encoding five genes: nucleocapsid (N), phosphoprotein (P), glycoprotein (G), matrix protein (M), and polymerase (L) . Over the past two decades, VSV has been extensively used as a platform for the development of oncolytic viruses due to its broad cellular tropism, lack of human immunity, and extensive knowledge about its genome and infection cycle19,20. A highly-studied oncolytic VSV is the attenuated variant VSV-D51 (also referred to as VSV∆51 M) which carries a deletion of methionine 51 in the M protein20–22. This mutation abolishes the ability of the M protein to inhibit cellular gene expression, a function that the wildtype variant achieves by blocking nuclear export of mRNAs. Consequently, normal cells can mount an antiviral response and are resistant to infection by VSV-D51 . In contrast, most tumor cells have defects in their innate immune responses and remain susceptible to this attenuated virus. Thus, although VSV-D51 infects a wide range of cell lines20, it exhibits limited efficacy in ","cbCaikGi7rBB3MPZ","https://ap.wps.com/l/cbCaikGi7rBB3MPZ","pdf",2823119,11,"English","# Results\n## Resistance to VSV-D51 is partial and heterogeneous among CT26 cells","[{\"question\":\"What virus and cell model are used to study resistance mechanisms?\",\"answer\":\"The study focuses on VSV-D51 and murine colon carcinoma CT26 cells. Two CT26-derived resistant clones (C1 and C4) are isolated to compare distinct resistance behaviors.\"},{\"question\":\"How does the resistance profile differ between the two clones?\",\"answer\":\"One clone shows strong resistance associated with elevated cytokine-mediated antiviral responses. The other clone shows lower-level resistance involving cytoskeletal reorganization, small GTPase signaling, and cell structural changes.\"},{\"question\":\"What do the findings suggest about oncolytic virotherapy resistance?\",\"answer\":\"Tumor cells can deploy heterogeneous resistance mechanisms against oncolytic viruses, which can act as a barrier and influence therapeutic efficacy.\"}]","Murine colon cancer derived cells exhibit heterogeneous resistance profiles against an oncolytic virus | PDF",1790017355,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97eef10b4bca1a4e230cc6aeb9a5eecb.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d5d694ff5e9c60513c52e99464ed905.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b53344dd773762d706ff33a0170bedb9.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/595dd0230fdef7859d3e81a17951b522.webp",980,1287]